DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
80.27
-1.35 (-1.65%)
At close: May 5, 2025, 4:00 PM
80.00
-0.27 (-0.34%)
Pre-market: May 6, 2025, 4:22 AM EDT
DexCom Revenue
DexCom had revenue of $1.04B in the quarter ending March 31, 2025, with 12.49% growth. This brings the company's revenue in the last twelve months to $4.15B, up 9.11% year-over-year. In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth.
Revenue (ttm)
$4.15B
Revenue Growth
+9.11%
P/S Ratio
7.62
Revenue / Employee
$402,718
Employees
10,300
Market Cap
31.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
DXCM News
- 1 day ago - DexCom: Growth Is Reaccelerating But Don't Ignore The Risks - Seeking Alpha
- 3 days ago - Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism - FXEmpire
- 3 days ago - Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring. - Barrons
- 4 days ago - DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Dexcom beats quarterly sales estimates, reiterates annual forecast - Reuters
- 4 days ago - Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program - Business Wire
- 5 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 19 days ago - Healthy Returns: What drugmakers are saying about Trump's looming pharmaceutical tariffs - CNBC